- Home
- CRBP vs RMBI Comparison
CRBP vs RMBI Comparison
Compare CRBP & RMBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CRBP | RMBI |
|---|---|---|
| Founded | 2009 | 1887 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 134.8M | 132.1M |
| IPO Year | 2014 | 2019 |
Fundamental Metrics
Financial Performance| Metric | CRBP | RMBI |
|---|---|---|
| Price | $9.41 | $13.33 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $45.60 | N/A |
| AVG Volume (30 Days) | ★ 182.7K | 17.0K |
| Earning Date | 06-15-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 4.51% |
| EPS Growth | N/A | ★ 1.10 |
| EPS | N/A | ★ 0.82 |
| Revenue | ★ $4,822,272.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $99.00 | N/A |
| P/E Ratio | ★ N/A | $16.16 |
| Revenue Growth | ★ 97.62 | N/A |
| 52 Week Low | $4.64 | $11.80 |
| 52 Week High | $20.56 | $15.24 |
Technical Indicators
Market Signals| Indicator | CRBP | RMBI |
|---|---|---|
| Relative Strength Index (RSI) | 57.91 | 32.85 |
| Support Level | $8.80 | $13.02 |
| Resistance Level | $9.69 | $14.31 |
| Average True Range (ATR) | 0.62 | 0.35 |
| MACD | 0.21 | -0.08 |
| Stochastic Oscillator | 62.75 | 13.53 |
Price Performance
Historical ComparisonAbout CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
About RMBI Richmond Mutual Bancorporation Inc.
Richmond Mutual Bancorp Inc is a United States-based banking company. Its principal business consists of attracting deposits from the general public & brokered deposits and investing those funds predominantly in loans secured by commercial and multi-family real estate, first mortgages on owner-occupied, one-to four-family residences, a variety of consumer loans, direct financing leases, and commercial and industrial loans. The company has one reportable segment which is Community Banking.